C

Calithera Biosciences Inc
F:2CB

Watchlist Manager
Calithera Biosciences Inc
F:2CB
Watchlist
Price: 3.86 EUR -2.53% Market Closed
Market Cap: 1m EUR

Relative Value

2CB price has not been updated for more than 5 months. This may indicate that the stock has been delisted.
2CB doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of 2CB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2CB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0.1
Industry
24.1
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
21.8
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
23.8
vs History
vs Industry
Median 3Y
0.1
Median 5Y
0.1
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
6.3
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
6.7
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
7.9
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
6.3
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.8
Industry
5.5

Multiples Across Competitors

2CB Competitors Multiples
Calithera Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Calithera Biosciences Inc
F:2CB
1m EUR 0 -0.1 0.6 0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 678 969.3 -160 071.1 -194 377.4 -192 159.4
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091.8 -533.8 -581.2 -565.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.5 1 212.2 163.5 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/S Multiple
Revenue Growth P/S to Growth
US
C
Calithera Biosciences Inc
F:2CB
Average P/S: 3 368 112.9
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 678 969.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 091.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.5
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
C
Calithera Biosciences Inc
F:2CB
Average P/E: 191.6
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 071.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 212.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Calithera Biosciences Inc
F:2CB
Average EV/EBITDA: 36
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Calithera Biosciences Inc
F:2CB
Average EV/EBIT: 41.5
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 159.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A